Key result
Patients with type 3 spinal muscular atrophy and three copies of SMN2 had a lower probability of remaining ambulant after 10 years of disease duration compared to those with four copies.
Why the study?
New therapies change the natural history of spinal muscular atrophy, prompting the need to describe patients and the course of type 3 SMA before disease-modifying treatments became available.
Observational (n=790)
SMN2 copy number, sex, and age of disease onset are important prognostic factors for the natural course and ambulation in type 3 spinal muscular atrophy.
Answers are grounded in this paper and cite their sources.
Offers pre-treatment SMA3 benchmarks from Polish registry; leaves open real-world treatment effects in rare neuromuscular disease.
BACKGROUND: Spinal muscular atrophy (SMA) is one of the most frequent and severe genetic diseases leading to premature death or severe motor disability. New therapies have been developed in recent years that change the natural history of the disease. The aim of this study is to describe patients included in the Polish Registry of SMA, with a focus on the course of type 3 SMA (SMA3) before the availability of disease-modifying treatments. RESULTS: 790 patients with SMA were included in the registry (173 with type 1 [SMA1], 218 with type 2 [SMA2], 393 with SMA3, and six with type 4 SMA [SMA4]), most (52%) of whom were adults. Data on SMN2 gene copy number were available for 672 (85%) patients. The mean age of onset was 5 months for SMA1, 11.5 months for SMA2, and 4.5 years for SMA3. In patients with SMA3, the first symptoms occurred earlier in those with three copies of SMN2 than in those with four copies of SMN2 (3.2 years vs. 6.7 years). The age of onset of SMA3 was younger in girls than in boys (3.1 years vs. 5.7 years), with no new cases observed in women older than 16 years. Male patients outnumbered female patients, especially among patients with SMA3b (49 female vs. 85 male patients) and among patients with SMA3 with four copies of SMN2 (30 female vs. 69 male patients). 44% of patients with SMA3 were still able to walk; in those who were not still able to walk, the mean age of immobilization was 14.0 years. Patients with SMA3a (age of onset < 3 years) and three copies of SMN2 had significantly worse prognosis for remaining ambulant than patients with SMA3b (age of onset ≥ 3 years) and four copies of SMN2. CONCLUSIONS: The Registry of SMA is an effective tool for assessing the disease course in the real world setting. SMN2 copy number is an important prognostic factor for the age of onset and ambulation in SMA3. Sex and age of disease onset also strongly affect the course of SMA. Data supplied by this study can aid treatment decisions.
No takes yet. Share an insight, caveat, or question.
Łusakowska et al. (2021) conducted an observational in Spinal muscular atrophy (n=790). Three copies of SMN2 vs. Four copies of SMN2 was evaluated on Probability of remaining ambulant after 10 years of disease (p=<0.0001). Patients with type 3 spinal muscular atrophy and three copies of SMN2 had a lower probability of remaining ambulant after 10 years of disease duration compared to those with four copies.
Synapse has enriched 10 related papers. Consider them for comparative context: